Soligenix reaffirms 2026 Phase 3 milestones as global regulatory support grows
Soligenix (NASDAQ:SNGX) reported financial results for the full year ended December 31, 2025, on March 31, 2026, emphasizing a clear pathway toward critical late-stage clinical data readouts.











